BNKL — Bionik Laboratories Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -458.22% | ||
| Return on Equity | -768.84% | ||
| Operating Margin | -267.29% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.25 | 2.15 | 1.19 | 1.27 | 1.81 | n/a | n/a | 12.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bionik Laboratories Corp. is a robotics company, which provides neurological functional recovery solutions to stroke survivors and others with neurological and mobility challenges. It uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and deliver recovery for patients with neurological or mobility impairments. It has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. Its InMotion ARM, and InMotion ARM/HAND products are robotic therapies for the upper limbs. In addition to these fully developed, clinical rehabilitation solutions, it is also developing InMotion Home, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home. Its other products are InMotion Robots and InMotion CONNECT.
Directors
- Andre-Jacques Auberton-Herve CHM (59)
- Richard Russo CEO (41)
- Loren Wass OTH (59)
- Remi Gaston-Dreyfus IND (65)
- Peter Malone IND (71)
- Joseph Martin IND (74)
- Charles Matine IND (62)
- Michal Prywata IND (29)
- Audrey Thevenon IND (43)
- Last Annual
- March 31st, 2023
- Last Interim
- March 31st, 2023
- Incorporated
- June 25th, 2013
- Public Since
- June 12th, 2012
- No. of Shareholders
- 315
- No. of Employees
- 12
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 12,480,431
- Address
- 80 Coolidge Hill Road, WATERTOWN, 02472
- Web
- https://www.bioniklabs.com/
- Phone
- +1 6179264800
- Contact
- Richard Russo
- Auditors
- MNP LLP
Upcoming Events for BNKL
Similar to BNKL
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
What is the Bionik Laboratories share price?
As of Today at 19:03 UTC, shares in Bionik Laboratories are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Bionik Laboratories share price performed this year?
Shares in Bionik Laboratories last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Bionik Laboratories share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Bionik Laboratories?
There is no consensus recommendation for this security.
What is the Bionik Laboratories dividend yield?
Bionik Laboratories does not currently pay a dividend.
Does Bionik Laboratories pay a dividend?
Bionik Laboratories does not currently pay a dividend.
When does Bionik Laboratories next pay dividends?
Bionik Laboratories does not currently pay a dividend.
How do I buy Bionik Laboratories shares?
To buy shares in Bionik Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bionik Laboratories?
As of the previous close price of $0.00, shares in Bionik Laboratories had a market capitalisation of .
Where are Bionik Laboratories shares listed?
Here are the trading details for Bionik Laboratories:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BNKL
What kind of share is Bionik Laboratories?
Based on an overall assessment of its quality, value and momentum Bionik Laboratories is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bionik Laboratories share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Bionik Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionik Laboratories. Over the past six months, its share price has underperformed the S&P500 Index by -100%.
As of the last closing price of $0.00, shares in Bionik Laboratories were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bionik Laboratories PE Ratio?
The Bionik Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bionik Laboratories?
Bionik Laboratories' management team is headed by:
- Andre-Jacques Auberton-Herve - CHM
- Richard Russo - CEO
- Loren Wass - OTH
- Remi Gaston-Dreyfus - IND
- Peter Malone - IND
- Joseph Martin - IND
- Charles Matine - IND
- Michal Prywata - IND
- Audrey Thevenon - IND